Back to Search Start Over

Biocon accused of committing IP theft to create cancer biotech Bicara.

Authors :
Kansteiner, Fraiser
Source :
FierceBiotech; 10/24/2024, pN.PAG-N.PAG, 1p
Publication Year :
2024

Abstract

Shortly after Bicara Therapeutics raised more than $360 million in an IPO, the cancer biotech and its former parent company have been hit with accusations of intellectual property theft. [ABSTRACT FROM AUTHOR]

Details

Language :
English
Database :
Complementary Index
Journal :
FierceBiotech
Publication Type :
Periodical
Accession number :
180503527